Lantheus Holdings (LNTH) Total Non-Current Liabilities (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Total Non-Current Liabilities of $1.1 billion for Q1 2026, up 24.32% year-over-year from $872.3 million in Q1 2025, and up 5.31% quarter-over-quarter from $1.0 billion in Q4 2025.
Lantheus Holdings (LNTH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Total Non-Current Liabilities for 13 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 24.32% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 24.32% YoY), while the FY2025 annual figure was $1.0 billion, up 16.71% from the prior year.
- Total Non-Current Liabilities rose to $1.1 billion in Q1 2026 per LNTH's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q3 2025 and bottomed at $395.8 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $813.2 million across 5 years, with a median of $851.6 million in 2022.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 124.98% — and 2024, when it declined 6.63%.
- Lantheus Holdings' Total Non-Current Liabilities stood at $851.6 million in 2022, then retreated by 4.61% to $812.3 million in 2023, then increased by 8.62% to $882.3 million in 2024, then increased by 16.71% to $1.0 billion in 2025, then climbed by 5.31% to $1.1 billion in 2026.
- Business Quant data shows LNTH's Total Non-Current Liabilities at $1.1 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Bn |
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.16 Bn |
| Jun 30, 2025 | 949.16 Mn |
| Mar 31, 2025 | 872.29 Mn |
| Dec 31, 2024 | 882.33 Mn |
| Sep 30, 2024 | 846.69 Mn |
| Jun 30, 2024 | 888.05 Mn |
| Mar 31, 2024 | 822.69 Mn |
| Dec 31, 2023 | 812.34 Mn |
| Sep 30, 2023 | 760.00 Mn |
| Jun 30, 2023 | 782.08 Mn |
| Mar 31, 2023 | 881.13 Mn |
| Dec 31, 2022 | 851.57 Mn |
| Sep 30, 2022 | 411.40 Mn |
| Jun 30, 2022 | 396.88 Mn |
| Mar 31, 2022 | 395.80 Mn |
| Dec 31, 2021 | 378.51 Mn |
| Sep 30, 2021 | 258.83 Mn |